KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Gains from Sales and Divestitures (2018 - 2020)

Historic Gains from Sales and Divestitures for Aquestive Therapeutics (AQST) over the last 3 years, with Q4 2020 value amounting to $64000.0.

  • Aquestive Therapeutics' Gains from Sales and Divestitures fell 4880.0% to $64000.0 in Q4 2020 from the same period last year, while for Dec 2020 it was $64000.0, marking a year-over-year decrease of 4880.0%. This contributed to the annual value of $64000.0 for FY2020, which is 4880.0% down from last year.
  • According to the latest figures from Q4 2020, Aquestive Therapeutics' Gains from Sales and Divestitures is $64000.0, which was down 4880.0% from $64000.0 recorded in Q3 2020.
  • In the past 5 years, Aquestive Therapeutics' Gains from Sales and Divestitures registered a high of $125000.0 during Q4 2019, and its lowest value of $29802.0 during Q3 2018.
  • In the last 3 years, Aquestive Therapeutics' Gains from Sales and Divestitures had a median value of $60000.0 in 2018 and averaged $61680.2.
  • Per our database at Business Quant, Aquestive Therapeutics' Gains from Sales and Divestitures surged by 21877.06% in 2019 and then tumbled by 4880.0% in 2020.
  • Over the past 3 years, Aquestive Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $60000.0 in 2018, then skyrocketed by 108.33% to $125000.0 in 2019, then tumbled by 48.8% to $64000.0 in 2020.
  • Its Gains from Sales and Divestitures was $64000.0 in Q4 2020, compared to $64000.0 in Q3 2020 and $60000.0 in Q2 2020.